Limits...
The use of nanoencapsulation to decrease human skin irritation caused by capsaicinoids.

Contri RV, Frank LA, Kaiser M, Pohlmann AR, Guterres SS - Int J Nanomedicine (2014)

Bottom Line: Capsaicin, a topical analgesic used in the treatment of chronic pain, has irritant properties that frequently interrupt its use.In this work, the effect of nanoencapsulation of the main capsaicinoids (capsaicin and dihydrocapsaicin) on skin irritation was tested in humans.Thirty-one percent of volunteers reported slight irritation one hour after application of CH-NC-CP, while moderate (46% [CH-ET-CP] and 23% [commercial product]) and severe (8% [CH-ET-CP] and 69% [commercial product]) irritation were described for the formulations containing free capsaicinoids.

View Article: PubMed Central - PubMed

Affiliation: Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.

ABSTRACT
Capsaicin, a topical analgesic used in the treatment of chronic pain, has irritant properties that frequently interrupt its use. In this work, the effect of nanoencapsulation of the main capsaicinoids (capsaicin and dihydrocapsaicin) on skin irritation was tested in humans. Skin tolerance of a novel vehicle composed of chitosan hydrogel containing nonloaded nanocapsules (CH-NC) was also evaluated. The chitosan hydrogel containing nanoencapsulated capsaicinoids (CH-NC-CP) did not cause skin irritation, as measured by an erythema probe and on a visual scale, while a formulation containing free capsaicinoids (chitosan gel with hydroalcoholic solution [CH-ET-CP]) and a commercially available capsaicinoids formulation caused skin irritation. Thirty-one percent of volunteers reported slight irritation one hour after application of CH-NC-CP, while moderate (46% [CH-ET-CP] and 23% [commercial product]) and severe (8% [CH-ET-CP] and 69% [commercial product]) irritation were described for the formulations containing free capsaicinoids. When CH-NC was applied to the skin, erythema was not observed and only 8% of volunteers felt slight irritation, which demonstrates the utility of the novel vehicle. A complementary in vitro skin permeation study showed that permeation of capsaicinoids through an epidermal human membrane was reduced but not prevented by nanoencapsulation.

Show MeSH

Related in: MedlinePlus

Skin erythema measured by electronic probe. The results indicate a ratio between the initial values (before application of formulation) and the final value at every measuring time point.Notes: Significant differences observed (P<0.05): *CH-ET-CP versus no formulation; **commercial formulation versus no formulation.Abbreviations: CH, chitosan gel; NC, nanocapsules; CP, capsaicinoids; ET, ethanolic solution; Commercial, commercial formulation.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3928459&req=5

f3-ijn-9-951: Skin erythema measured by electronic probe. The results indicate a ratio between the initial values (before application of formulation) and the final value at every measuring time point.Notes: Significant differences observed (P<0.05): *CH-ET-CP versus no formulation; **commercial formulation versus no formulation.Abbreviations: CH, chitosan gel; NC, nanocapsules; CP, capsaicinoids; ET, ethanolic solution; Commercial, commercial formulation.

Mentions: The final erythema value, measured by the Mexameter probe (CK Electronic), was determined as the ratio between measurements at the predetermined time and time zero, corresponding to the data obtained before application of the formulation. This data correction was performed because the time zero measurements for erythema differed considerably between the volunteers. Graphs of the final erythema value as a function of time are shown in Figure 3. The formulations were compared with the untreated control area at each time point, and when significantly (P<0.05) higher erythema values were obtained, the formulation was considered to have caused skin erythema.


The use of nanoencapsulation to decrease human skin irritation caused by capsaicinoids.

Contri RV, Frank LA, Kaiser M, Pohlmann AR, Guterres SS - Int J Nanomedicine (2014)

Skin erythema measured by electronic probe. The results indicate a ratio between the initial values (before application of formulation) and the final value at every measuring time point.Notes: Significant differences observed (P<0.05): *CH-ET-CP versus no formulation; **commercial formulation versus no formulation.Abbreviations: CH, chitosan gel; NC, nanocapsules; CP, capsaicinoids; ET, ethanolic solution; Commercial, commercial formulation.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3928459&req=5

f3-ijn-9-951: Skin erythema measured by electronic probe. The results indicate a ratio between the initial values (before application of formulation) and the final value at every measuring time point.Notes: Significant differences observed (P<0.05): *CH-ET-CP versus no formulation; **commercial formulation versus no formulation.Abbreviations: CH, chitosan gel; NC, nanocapsules; CP, capsaicinoids; ET, ethanolic solution; Commercial, commercial formulation.
Mentions: The final erythema value, measured by the Mexameter probe (CK Electronic), was determined as the ratio between measurements at the predetermined time and time zero, corresponding to the data obtained before application of the formulation. This data correction was performed because the time zero measurements for erythema differed considerably between the volunteers. Graphs of the final erythema value as a function of time are shown in Figure 3. The formulations were compared with the untreated control area at each time point, and when significantly (P<0.05) higher erythema values were obtained, the formulation was considered to have caused skin erythema.

Bottom Line: Capsaicin, a topical analgesic used in the treatment of chronic pain, has irritant properties that frequently interrupt its use.In this work, the effect of nanoencapsulation of the main capsaicinoids (capsaicin and dihydrocapsaicin) on skin irritation was tested in humans.Thirty-one percent of volunteers reported slight irritation one hour after application of CH-NC-CP, while moderate (46% [CH-ET-CP] and 23% [commercial product]) and severe (8% [CH-ET-CP] and 69% [commercial product]) irritation were described for the formulations containing free capsaicinoids.

View Article: PubMed Central - PubMed

Affiliation: Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.

ABSTRACT
Capsaicin, a topical analgesic used in the treatment of chronic pain, has irritant properties that frequently interrupt its use. In this work, the effect of nanoencapsulation of the main capsaicinoids (capsaicin and dihydrocapsaicin) on skin irritation was tested in humans. Skin tolerance of a novel vehicle composed of chitosan hydrogel containing nonloaded nanocapsules (CH-NC) was also evaluated. The chitosan hydrogel containing nanoencapsulated capsaicinoids (CH-NC-CP) did not cause skin irritation, as measured by an erythema probe and on a visual scale, while a formulation containing free capsaicinoids (chitosan gel with hydroalcoholic solution [CH-ET-CP]) and a commercially available capsaicinoids formulation caused skin irritation. Thirty-one percent of volunteers reported slight irritation one hour after application of CH-NC-CP, while moderate (46% [CH-ET-CP] and 23% [commercial product]) and severe (8% [CH-ET-CP] and 69% [commercial product]) irritation were described for the formulations containing free capsaicinoids. When CH-NC was applied to the skin, erythema was not observed and only 8% of volunteers felt slight irritation, which demonstrates the utility of the novel vehicle. A complementary in vitro skin permeation study showed that permeation of capsaicinoids through an epidermal human membrane was reduced but not prevented by nanoencapsulation.

Show MeSH
Related in: MedlinePlus